CLINICAL USE


Alpha-adrenoceptor blocker:Hypertension Congestive heart failure Raynaud’s syndrome Benign prostatic hyperplasia (BPH)

DOSE IN NORMAL RENAL FUNCTION

0.5–20 mg daily in 2–3 divided doses Raynaud’s syndrome, BPH: 0.5–2 mg twice daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :419.9
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :97
  • %Excreted unchanged in urine &nbsp &nbsp :
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1.2–1.5
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :2–4/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Anaesthetics: enhanced hypotensive effect
  • Antidepressants: enhanced hypotensive effect with MAOIs
  • Beta-blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect
  • Calcium-channel blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect
  • Diuretics: enhanced hypotensive effect, increased risk of first dose hypotensive effect
  • Moxisylyte: possibly severe postural hypotension when used in combination
  • Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments